Pharma & Life Sciences

FDA Warning Letter to Premium Health Management

The FDA issued a warning letter to Premium Health Management Inc. for misbranding compounded semaglutide and tirzepatide products. The company's website made false or misleading claims about the products, suggesting they were compounded by Premium Health when they were not, and implying FDA approval or evaluation.

EMA Draft Guidance on Clinical Trials During Public Health Emergencies

The European Medicines Agency (EMA) has published draft guidance for conducting clinical trials during public health emergencies. This guidance, open for consultation until April 30, 2026, aims to streamline the authorization of new trials and modifications to ongoing trials.

Frito-Lay Recalls Chips for Undeclared Milk Allergen

Frito-Lay is voluntarily recalling select 8 oz. bags of Miss Vickie's Spicy Dill Pickle Potato Chips due to undeclared milk allergen. The recall affects products distributed in Arkansas, Louisiana, Mississippi, New Mexico, Oklahoma, and Texas. No allergic reactions have been reported to date.

FDA Safety Communication on Choking Rescue Protocols and Devices

The FDA is issuing a safety communication to encourage the public and healthcare providers to follow established choking rescue protocols before using anti-choking devices. The agency highlights that established protocols, such as back blows and abdominal thrusts, are the most effective method and that using devices first could delay life-saving actions.

FDA Warning Letter to Las Americas Supermercado#2 Inc.

The FDA issued a warning letter to Las Americas Supermercado#2 Inc. for significant violations of the Foreign Supplier Verification Program (FSVP) regulation. The inspection revealed the company failed to develop and maintain an FSVP for imported foods, a violation of the Federal Food, Drug, and Cosmetic Act.

MHRA Field Safety Notices - February 23-27, 2026

The MHRA has published a list of five Field Safety Notices (FSNs) issued between February 23-27, 2026, for medical devices. These notices are for informational purposes, and recipients are advised to contact the manufacturer with any questions.

FDA Draft Guidance on 3-Year Exclusivity for Drug Products

The FDA has issued draft guidance to assist applicants requesting 3-year exclusivity for drug products. The guidance, available for public comment, clarifies the statutory and regulatory criteria for eligibility and provides recommendations on request content and format. This aims to support the Drug Competition Action Plan.

FDA Final Guidance on Post-Approval Safety Data Reporting

The FDA has issued final guidance on post-approval safety data reporting, updating standards for managing and reporting individual case safety reports. This guidance clarifies the use of new data sources and replaces previous versions from 2003 and a draft from March 2024.

FDA Guidance on Real-World Data for Medicine Safety Assessment

The FDA has issued final guidance on using real-world data for medicine safety assessments, replacing a previous draft and withdrawing an older guidance. This document provides principles for planning, designing, analyzing, and reporting non-interventional studies utilizing real-world data for drugs and biological products.

FDA Warning Letter to Yuyao City Boss Vegetable Factory

The FDA issued a warning letter to Yuyao City Boss Vegetable Factory Co. Ltd. for serious violations of food safety regulations, including failure to maintain processing records and fabrication of data. The violations relate to acidified foods intended for export to the United States.